Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Cash from Financing Activities: 2014-2024

Historic Cash from Financing Activities for Editas Medicine (EDIT) over the last 11 years, with Dec 2024 value amounting to $56.0 million.

  • Editas Medicine's Cash from Financing Activities was N/A to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.7 million, marking a year-over-year change of. This contributed to the annual value of $56.0 million for FY2024, which is 52.54% down from last year.
  • According to the latest figures from FY2024, Editas Medicine's Cash from Financing Activities is $56.0 million, which was down 52.54% from $118.0 million recorded in FY2023.
  • In the past 5 years, Editas Medicine's Cash from Financing Activities ranged from a high of $282.1 million in FY2021 and a low of $1.3 million during FY2022.
  • Its 3-year average for Cash from Financing Activities is $58.5 million, with a median of $56.0 million in 2024.
  • Per our database at Business Quant, Editas Medicine's Cash from Financing Activities plummeted by 99.54% in 2022 and then spiked by 9,093.07% in 2023.
  • Yearly analysis of 5 years shows Editas Medicine's Cash from Financing Activities stood at $224.1 million in 2020, then climbed by 25.87% to $282.1 million in 2021, then plummeted by 99.54% to $1.3 million in 2022, then soared by 9,093.07% to $118.0 million in 2023, then tumbled by 52.54% to $56.0 million in 2024.